BHCM
CTNM

Brevan Howard Capital Management’s Contineum Therapeutics CTNM Stock Holding History

Brevan Howard Capital Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-42,178
Closed -$551K – 2656
2026
Q1 		$551K Buy
42,178
+22,752
+117% +$305K ﹤0.01% 1240
2025
Q4 		$222K Buy
+19,426
New +$222K ﹤0.01% 1527

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Brevan Howard Capital Management's CTNM Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Contineum Therapeutics (CTNM) in Q2 2026, closing a stake of 42,178 shares — an estimated $551K sold.

Brevan Howard Capital Management first reported a position in CTNM in Q4 2025 and held it in 2 quarters. The position peaked at $551K in Q1 2026. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Contineum Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 42,178 Contineum Therapeutics shares in Q2 2026, an estimated $551K.
  • Brevan Howard Capital Management first reported a position in Contineum Therapeutics in Q4 2025 and held it in 2 quarters.
  • Brevan Howard Capital Management's Contineum Therapeutics position peaked at $551K in Q1 2026.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.